PPARα agonist fenofibrate attenuates iron-induced liver injury in mice by modulating the Sirt3 and β-catenin signaling.

Autor: Mandala, Ashok, Chen, William J., Armstrong, Austin, Malhotra, Milan R., Chavalmane, Sanmathi, McCommis, Kyle S., Chen, Anping, Carpenter, Danielle, Biswas, Pratim, Gnana-Prakasam, Jaya P.
Předmět:
Zdroj: American Journal of Physiology: Gastrointestinal & Liver Physiology; Sep2021, Vol. 321 Issue 3, pG262-G269, 8p
Abstrakt: Iron accumulation is frequently associated with chronic liver diseases. However, our knowledge on how iron contributes to the liver injury is limited. Aberrant Wnt/b-catenin signaling is a hallmark of several hepatic pathologies. We recently reported that peroxisome proliferator-activated receptor a (PPARa) agonist, fenofibrate, prevents iron-induced oxidative stress and b-catenin signaling by chelating the iron. Sirtuin3 (Sirt3), a type of NADþ-dependent deacetylase, that plays a critical role in metabolic regulation was found to prevent ischemia reperfusion injury (IRI) by normalizing the Wnt/β-catenin pathway. In the present study, we explored if fenofibrate prevents iron-induced liver injury by regulating the Sirt3 and β-catenin signaling. In vitro and in vivo iron treatment resulted in the downregulation of PPARa, Sirt3, active β-catenin, and its downstream target gene c-Myc in the mouse liver. Pharmacological activation of Sirt3, both in vitro and in vivo, by Honokiol (HK), a known activator of Sirt3, abrogated the inhibitory effect of iron overload on active β-catenin expression and prevented the iron-induced upregulation of a smooth muscle actin (aSMA) and TGFb expression. Intrinsically, PPARa knockout mice showed significant downregulation of hepatic Sirt3 levels. In addition, treatment of iron overload mice with PPARa agonist fenofibrate reduced hepatic iron accumulation and prevented iron-induced downregulation of liver Sirt3 and active β-catenin, mitigating the progression of fibrosis. Thus, our results establish a novel link between hepatic iron and PPARa, Sirt3, and β-catenin signaling. Further exploration on the mechanisms by which fenofibrate ameliorates iron-induced liver injury likely has significant therapeutic impact on iron-associated chronic liver diseases. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index